Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other financing activities: 2019-2024

Historic Other financing activities for Heron Therapeutics (HRTX) over the last 6 years, with Dec 2024 value amounting to $303,000.

  • Heron Therapeutics' Other financing activities fell 492.31% to -$51,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $168,000, marking a year-over-year decrease of 50.59%. This contributed to the annual value of $303,000 for FY2024, which is 133.55% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Other financing activities is $303,000, which was up 133.55% from -$903,000 recorded in FY2023.
  • Heron Therapeutics' Other financing activities' 5-year high stood at $6.8 million during FY2020, with a 5-year trough of -$1.5 million in FY2022.
  • In the last 3 years, Heron Therapeutics' Other financing activities had a median value of -$903,000 in 2023 and averaged -$710,000.
  • In the last 5 years, Heron Therapeutics' Other financing activities plummeted by 131.06% in 2022 and then surged by 133.55% in 2024.
  • Heron Therapeutics' Other financing activities (Yearly) stood at $6.8 million in 2020, then fell by 27.12% to $4.9 million in 2021, then slumped by 131.06% to -$1.5 million in 2022, then soared by 40.98% to -$903,000 in 2023, then soared by 133.55% to $303,000 in 2024.